The expression of FTO and ALKBH5 has shown discrepancies in studies on RCC patients, with some indicating oncogenic roles [19,20,21,22] and others suggesting tumor-suppressive roles [23,24]. The gene discussed is ALKBH5; the disease is renal cell carcinoma.